Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 10, No. 1-4, 2012
Issue release date: April 2012
Section title: Paper

Open Access Gateway

Neurodegenerative Dis 2012;10:149–152

Software Tool for Improved Prediction of Alzheimer’s Disease

Soininen H.a · Mattila J.b · Koikkalainen J.b · van Gils M.b · Hviid Simonsen A.c · Waldemar G.c · Rueckert D.d · Thurfjell L.e · Lötjönen J.b · for the Alzheimer’s Disease Neuroimaging Initiative
aUniversity of Eastern Finland, Kuopio University Hospital, Kuopio, and bVTT Technical Research Centre of Finland, Tampere, Finland; cDepartment of Neurology, Rigshospitalet, Copenhagen, Denmark; dImperial College London, London, UK; eGE Healthcare, Uppsala, Sweden
email Corresponding Author

Prof. Hilkka Soininen

Department of Neurology

University of Eastern Finland

PO Box 1627, FI–70211 Kuopio (Finland)

Tel. +358 17 173 012, E-Mail hilkka.soininen@uef.fi

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: Diagnostic criteria of Alzheimer’s disease (AD) emphasize the integration of clinical data and biomarkers. In practice, collection and analysis of patient data vary greatly across different countries and clinics. Objective: The goal was to develop a versatile and objective clinical decision support system that could reduce diagnostic errors and highlight early predictors of AD. Methods: Novel data analysis methods were developed to derive composite disease indicators from heterogeneous patient data. Visualizations that communicate these findings were designed to help the interpretation. The methods were implemented with a software tool that is aimed for daily clinical practice. Results: With the tool, clinicians can analyze available patients as a whole, study them statistically against previously diagnosed cases, and characterize the patients with respect to having AD. The tool is able to work with virtually any patient measurement data, as long as they are stored in electronic format or manually entered into the system. For a subset of patients from the test cohort, the tool was able to predict conversion to AD at an accuracy of 93.6%. Conclusion: The software tool developed in this study provides objective information for early detection and prediction of AD based on interpretable visualizations of patient data.

© 2011 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Paper

Received: June 30, 2011
Accepted: September 01, 2011
Published online: December 09, 2011
Issue release date: April 2012

Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 1

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: http://www.karger.com/NDD

Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.